Patents Examined by Susanna Moore
  • Patent number: 11117890
    Abstract: The present invention provides substituted isoindole compounds which are selective allosteric EGFR inhibitors, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances, generally of Formula: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: September 14, 2021
    Assignee: Hoffman La-Roche Inc.
    Inventors: Georg Jaeschke, Antonio Ricci, Daniel Rueher, Sandra Steiner, Martin Duplessis, Yvonne Alice Nagel, Bernd Kuhn
  • Patent number: 11111267
    Abstract: The present invention provides two crystal forms of jervine and their preparation methods, and their application as antitumor agents. The preparation methods of these two crystal forms are simple, high yield and can be easily scaled to industry scale.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: September 7, 2021
    Inventor: Xianchang Gong
  • Patent number: 11104674
    Abstract: The present invention provides novel compounds having the general formula: wherein R1 to R4, A, W, Q and Y are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: August 31, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Zhanling Cheng, Xingchun Han, Min Jiang, Jianhua Wang, Yongguang Wang, Song Yang
  • Patent number: 11104687
    Abstract: The present invention provides solid forms of compounds useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, methods of producing the same, and methods of using the same in the treatment of ACC-mediated diseases.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: August 31, 2021
    Assignee: Gilead Apollo, LLC
    Inventors: Geraldine C. Harriman, Jon P. Lawson, Xiaowei Yang
  • Patent number: 11098062
    Abstract: The present invention relates to novel novel monocyclic and bicyclic ring system substituted carbanucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: August 24, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tongfei Wu, Dirk Brehmer, Lijs Beke, An Boeckx, Gaston Stanislas Marcella Diels, Edward Charles Lawson, Lieven Meerpoel, Vineet Pande, Marcus Cornelis Bernardus Catharina Paradé, Wim Bert Griet Schepens, Weimei Sun, Johannes Wilhelmus John F. Thuring, Marcel Viellevoye
  • Patent number: 11098060
    Abstract: The present application relates to a macrocycle containing aminopyrazole and pyrimidine, which is represented by formula (I), a pharmaceutical composition thereof, and a use thereof in inhibiting tropomyosin receptor kinase (Trk) activity and in treating diseases in mammals that are mediated by Trk.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: August 24, 2021
    Assignees: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., CENTAURUS BIOPHARMA CO., LTD., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD.
    Inventors: Liguang Dai, Xiaowei Duan, Yanqing Yang, Xijie Liu, Hongjuan Li, Na Zhao, Yinghui Sun, Fansheng Kong, Jiuqing Zhang, Yizhong Zhu, Ling Yang, Fei Liu
  • Patent number: 11091491
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: October 1, 2019
    Date of Patent: August 17, 2021
    Assignee: Incyte Corporation
    Inventors: Artem Shvartsbart, Stacey Shepard, Andrew P. Combs, Lixin Shao, Nikoo Falahatpisheh, Ge Zou, Andrew W. Buesking, Richard B. Sparks, Eddy W. Yue, Ravi Kumar Jalluri
  • Patent number: 11091489
    Abstract: Provided herein are crystalline forms of a triazolopyrimidine compound, which is useful for treating a PRC2-mediated disease or disorder.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: August 17, 2021
    Assignee: Novartis AG
    Inventors: Ying Huang, Bo Liu, Liang Mao, Long Wang, Liladhar Murlidhar Waykole, Lijun Zhang
  • Patent number: 11091498
    Abstract: Provided herein are compounds of formula (I): and salts thereof. Also provided are pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula (I), and therapeutic methods for treating diseases such as cancer, a bacterial infection or a fungal infection using compounds of formula (I).
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: August 17, 2021
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Edmond J. LaVoie, Ajit K. Parhi
  • Patent number: 11091485
    Abstract: Provided is an imidazo[1?,2?:1,6]pyrido[2,3-d]pyrimidine compound of general formula (I). The compound can be used in treating a cell proliferative disorder and is a cyclin-dependent kinase (CDK) inhibitor with broad-spectrum and strong activity.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: August 17, 2021
    Assignee: SHENGKE PHARMACEUTICALS (JIANGSU) LTD.
    Inventors: Bin Liu, Hang Cheng, Weiyan Xiong, Chenggang Zhang, Chengzhi Yu
  • Patent number: 11084814
    Abstract: The purpose of the present invention is to provide a compound that has excellent CDK4/6 inhibitory activity. The present invention is a compound represented by formula (I) or a pharmaceutically acceptable salt of the compound.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: August 10, 2021
    Assignee: Teijin Pharma Limited
    Inventors: Tsuyoshi Mizuno, Tomohiro Shimada, Gen Unoki, Akinobu Maruyama, Kosuke Sasaki, Takuya Yokosaka, Hiroshi Takahashi, Kyohei Horie, Yuri Sakai
  • Patent number: 11084832
    Abstract: Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2, L, W1, W2, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: August 10, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Ana Z. Gonzalez Buenrostro, Hongyan Guo, Xiaochun Han, Lan Jiang, Jiayao Li, Michael L. Mitchell, Hyung-Jung Pyun, Scott D. Schroeder, Gregg M. Schwarzwalder, Nathan D. Shapiro, Devleena M. Shivakumar, Qiaoyin Wu, Hong Yang, Jennifer R. Zhang
  • Patent number: 11078214
    Abstract: The present invention provides a compound of Formula XXVII: wherein X is CH2 or O, and R1 is H or CH3; or a salt or a hydrate of the compound, and further provides a pharmaceutical composition comprising the compound of Formula XXVII and one or more acceptable pharmaceutical carriers. A method of treating a patient having cancer comprising administering a therapeutically effective amount of a compound of Formula XXVII, or a pharmaceutical composition comprising a compound of Formula XXVII and one or more acceptable pharmaceutical carriers to the patient is disclosed.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: August 3, 2021
    Assignee: Duquesne University of The Holy Spirit
    Inventor: Aleem Gangjee
  • Patent number: 11066409
    Abstract: Provided are a novel compound having an antagonistic activity for the P2X7 receptor, and a pharmaceutical composition having an antagonistic activity for the P2X7 receptor. The compound represented by Formula (I): wherein the symbols are defined in the specification, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: July 20, 2021
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Koji Masuda, Shuichi Sugiyama, Toru Yamada, Eiichi Kojima, Tomoyuki Ogawa, Naotake Kobayashi, Hiroyuki Kai
  • Patent number: 11059827
    Abstract: This invention relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: July 13, 2021
    Assignee: Blueprint Medicines Corporation
    Inventors: Steven Mark Wenglowsky, Chandrasekhar V. Miduturu, Neil Bifulco, Joseph L. Kim
  • Patent number: 11053258
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: July 6, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guanglin Luo, Prasanna Sivaprakasam, Gene M. Dubowchik, John E. Macor
  • Patent number: 11053253
    Abstract: Macrocyclic Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, and Formula VIII or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: July 6, 2021
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Avinash S. Phadke, Dawei Chen, Venkat Rao Gadhachanda, Joel Charles Barrish, Atul Agarwal, Kyle J. Eastman
  • Patent number: 11053252
    Abstract: Fused cyclic pyrimidine compounds, including tautomers thereof, and pharmaceutically acceptable salts, prodrugs, solvates and hydrates thereof, are disclosed having the general Formula I: These compounds are useful in methods for treating cancer, selectively targeting cancerous cells via the proton coupled folate transporter, folate receptor alpha, and/or folate receptor beta pathways, inhibiting GARFTase in cancerous cells, and selectively targeting activated macrophages in a patient having an autoimmune disease, such as rheumatoid arthritis.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: July 6, 2021
    Assignees: Duquesne University of the Holy Spirit, Wayne State University
    Inventors: Aleem Gangjee, Larry H. Matherly
  • Patent number: 11046697
    Abstract: This disclosure relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants, such as compounds of Formula (I):
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: June 29, 2021
    Inventors: Steven Mark Wenglowsky, Natasja Brooijmans, Chandrasekhar V. Miduturu, Neil Bifulco, Jr.
  • Patent number: 11046694
    Abstract: Provided herein are antibacterial compounds represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X, Y, R4, R5, and R6 are as defined herein. Also provided are pharmaceutical compositions comprising the compounds of Formula I.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: June 29, 2021
    Assignee: Entasis Therapeutics, Inc.
    Inventors: Janelle Comita-Prevoir, Thomas Francois Durand-Reville, Satenig Guler, Jan Romero, Mark Sylvester, Ruben Tommasi, Camilo Velez-Vega, Xiaoyun Wu, Jing Zhang